{"id":15094,"date":"2026-06-23T19:10:33","date_gmt":"2026-06-23T13:40:33","guid":{"rendered":"https:\/\/mdforlives.com\/blog\/?p=15094"},"modified":"2026-06-23T19:10:33","modified_gmt":"2026-06-23T13:40:33","slug":"glp-1-therapy-in-obesity-care","status":"publish","type":"post","link":"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/","title":{"rendered":"GLP-1 Therapy in Obesity Care: Why Staying on Treatment Is the Real Test"},"content":{"rendered":"<p><span data-contrast=\"auto\">A GLP-1 prescription can begin with clinical confidence and still end in uncertainty.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">That is the tension now shaping obesity care. The question is no longer only whether GLP-1 and GLP-1\/GIP therapies can support meaningful weight loss. The more\u00a0difficult question\u00a0is whether patients can stay on them long enough for that benefit to translate into durable care.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Globally, obesity is increasingly being treated as a chronic, relapsing condition rather than a short-term lifestyle problem. The World Health Organization\u2019s 2025 guidance on GLP-1 therapies for obesity reinforces this shift, positioning treatment within a broader model that includes long-term care, healthy diets, physical activity, clinical support, affordability, and health-system readiness [WHO, 2025]. A large real-world cohort study published in JAMA Network Open also showed why continuity matters: among adults with overweight or obesity starting GLP-1 receptor agonists, discontinuation within one year was common, especially among patients without type 2 diabetes [JAMA Network Open, 2025].<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Against this backdrop,\u00a0MDForLives\u00a0clinician-reported research across the USA, UK, Canada, France, Germany, and Italy reveals a clear pattern. GLP-1 therapy has crossed the belief threshold in obesity care. It has not yet crossed the delivery threshold.<\/span><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_74 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#Clinicians_Are_No_Longer_Questioning_Relevance\" >Clinicians Are No Longer Questioning Relevance\u00a0<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#Routine_Use_Depends_on_the_System_Around_the_Therapy\" >Routine Use Depends on the System Around the Therapy\u00a0<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#Real-World_Outcomes_Are_Trusted_But_Not_Taken_for_Granted\" >Real-World Outcomes Are Trusted, But Not Taken for Granted<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#Suitability_Is_Becoming_a_Question_of_Feasibility\" >Suitability Is Becoming a Question of Feasibility\u00a0<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#Discontinuation_Is_Often_Financial_Before_It_Is_Clinical\" >Discontinuation Is Often Financial Before It Is Clinical<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#Patient_Expectations_May_Be_the_Most_Underestimated_Risk\" >Patient Expectations May Be the Most Underestimated Risk\u00a0<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#The_Future_Impact_of_GLP-1_Therapy_Will_Be_Decided_Beyond_the_Prescription\" >The Future Impact of GLP-1 Therapy Will Be Decided Beyond the Prescription\u00a0<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#Closing_Perspective\" >Closing Perspective\u00a0<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#FAQs\" >FAQs<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#Why_is_GLP-1_continuation_important_in_obesity_care\" >Why is GLP-1 continuation important in obesity care?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#What_are_the_main_barriers_to_GLP-1_continuation\" >What are the main barriers to GLP-1 continuation?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#Are_GLP-1_therapies_considered_relevant_for_obesity_treatment_without_diabetes\" >Are GLP-1 therapies considered relevant for obesity treatment without diabetes?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#Why_do_GLP-1_outcomes_differ_between_clinical_trials_and_real-world_care\" >Why do GLP-1 outcomes differ between clinical trials and real-world care?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#What_will_shape_the_future_of_GLP-1_therapy_in_obesity_care\" >What will shape the future of GLP-1 therapy in obesity care?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Clinicians_Are_No_Longer_Questioning_Relevance\"><\/span><strong><span class=\"TextRun SCXW74727352 BCX8\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW74727352 BCX8\" data-ccp-parastyle=\"heading 2\">Clinicians Are No Longer Questioning Relevance<\/span><\/span><span class=\"EOP Selected SCXW74727352 BCX8\" data-ccp-props=\"{&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:160,&quot;335559739&quot;:80}\">\u00a0<\/span><\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span class=\"NormalTextRun SCXW217131605 BCX8\">More than 90% of clinicians in the\u00a0<\/span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW217131605 BCX8\">MDForLives<\/span><span class=\"NormalTextRun SCXW217131605 BCX8\">\u00a0research described GLP-1 or GLP-1\/GIP therapies as highly or moderately relevant to obesity management, with\u00a0<\/span><span class=\"NormalTextRun SCXW217131605 BCX8\">nearly three-quarters<\/span><span class=\"NormalTextRun SCXW217131605 BCX8\">\u00a0rating them as highly relevant.<\/span><\/p>\n<p><span data-contrast=\"auto\">That level of agreement signals a meaningful change. GLP-1 therapy is no longer being viewed as a niche or experimental\u00a0option. It has entered the clinical decision-making framework for obesity care.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">But relevance is\u00a0not the same as\u00a0readiness. Clinicians may believe in the therapy and still hesitate if continuation feels uncertain. This is where the insight becomes sharper: the barrier is not clinical acceptance. It is practical confidence.<\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Routine_Use_Depends_on_the_System_Around_the_Therapy\"><\/span><strong><span class=\"TextRun SCXW248212304 BCX8\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW248212304 BCX8\" data-ccp-parastyle=\"heading 2\">Routine Use Depends on the System Around the Therapy<\/span><\/span><span class=\"EOP Selected SCXW248212304 BCX8\" data-ccp-props=\"{&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:160,&quot;335559739&quot;:80}\">\u00a0<\/span><\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span data-contrast=\"auto\">At an overall level, around two-thirds of clinicians said they routinely consider GLP-1 therapy for obesity independent of diabetes, while another quarter\u00a0consider\u00a0it occasionally.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">On the surface, this suggests strong adoption. But country-level differences reveal how deeply system design shapes prescribing behavior. In the USA, more than 80% of clinicians reported routine consideration. In the UK, fewer than 40% described GLP-1 therapy as routine.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">This gap does not necessarily reflect a difference in clinical belief. It reflects different access pathways, funding structures, prescribing controls, and service capacity. NICE guidance and NHS England\u2019s phased commissioning approach for tirzepatide show how obesity pharmacotherapy access may depend on eligibility criteria,\u00a0prioritised\u00a0cohorts, and implementation capacity [NICE, 2024; NHS England, 2026].<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">For clinicians, this means adoption is filtered through system feasibility. A therapy may be\u00a0appropriate, but access rules decide how often it becomes a real\u00a0option.<\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Real-World_Outcomes_Are_Trusted_But_Not_Taken_for_Granted\"><\/span><strong><span class=\"TextRun SCXW77407677 BCX8\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW77407677 BCX8\" data-ccp-parastyle=\"heading 2\">Real-World Outcomes Are Trusted, But Not Taken for Granted<\/span><\/span><\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><img loading=\"lazy\" decoding=\"async\" data-attachment-id=\"15101\" data-permalink=\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/in-article-image-1-3\/\" data-orig-file=\"https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/In-Article-Image-1-1.png\" data-orig-size=\"800,400\" data-comments-opened=\"1\" data-image-meta=\"{&quot;aperture&quot;:&quot;0&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;0&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;0&quot;,&quot;iso&quot;:&quot;0&quot;,&quot;shutter_speed&quot;:&quot;0&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;0&quot;,&quot;alt&quot;:&quot;&quot;}\" data-image-title=\"In-Article Image 1\" data-image-description=\"\" data-image-caption=\"\" data-medium-file=\"https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/In-Article-Image-1-1-300x150.png\" data-large-file=\"https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/In-Article-Image-1-1.png\" class=\"aligncenter size-full wp-image-15101\" src=\"https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/In-Article-Image-1-1.png\" alt=\"clinical trial expectations compared with real-world GLP-1 therapy continuation challenges \" width=\"800\" height=\"400\" srcset=\"https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/In-Article-Image-1-1.png 800w, https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/In-Article-Image-1-1-300x150.png 300w, https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/In-Article-Image-1-1-768x384.png 768w\" sizes=\"auto, (max-width: 800px) 100vw, 800px\" \/><\/p>\n<p><span data-contrast=\"auto\">Clinician\u00a0confidence in GLP-1 outcomes\u00a0remains\u00a0strong, but it is not absolute.\u00a0More than 80% of respondents said real-world weight loss outcomes are aligned with clinical trial expectations.\u00a0Yet only 18% described outcomes as closely aligned, while 66% said they were only\u00a0somewhat aligned. Around 15% reported outcomes as often lower than expected or highly variable.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">This does not suggest that clinicians doubt GLP-1 therapy. Rather, it shows that real-world care introduces variables that trials cannot fully\u00a0contain.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Treatment may be interrupted. Titration may be delayed.\u00a0Coverage\u00a0may change. Side effects may affect persistence. Patients may lose motivation if expectations were not clearly set from the beginning.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">In other words, efficacy may be trusted, but durability is not assumed.<\/span><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Suitability_Is_Becoming_a_Question_of_Feasibility\"><\/span><strong><span class=\"TextRun SCXW59052416 BCX8\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW59052416 BCX8\" data-ccp-parastyle=\"heading 2\">Suitability Is Becoming a Question of Feasibility<\/span><\/span><span class=\"EOP Selected SCXW59052416 BCX8\" data-ccp-props=\"{&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:160,&quot;335559739&quot;:80}\">\u00a0<\/span><\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span data-contrast=\"auto\">Clinical eligibility and comorbidities\u00a0remain\u00a0the leading factor in patient selection, cited by 52% of clinicians. But 32% now\u00a0identify\u00a0expected adherence and patient motivation as the most\u00a0important factor.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">This is a quiet but important shift in obesity care. Clinicians are not only asking, \u201cIs this patient clinically eligible?\u201d They are also asking, \u201cCan this patient realistically continue therapy?\u201d<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Cost and coverage were cited directly by a smaller share of clinicians, but their indirect influence is much wider. If affordability or reimbursement is unstable, clinicians may become cautious even before treatment begins.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">The uncomfortable implication is that some patients may not start GLP-1 therapy despite being clinically suitable. Not because the therapy is inappropriate, but because continuation feels fragile from the outset.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<h2 aria-level=\"2\"><span class=\"ez-toc-section\" id=\"Discontinuation_Is_Often_Financial_Before_It_Is_Clinical\"><\/span><strong>Discontinuation Is Often Financial Before It Is Clinical<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span data-contrast=\"auto\">When clinicians were asked what most commonly limits long-term continuation, more than half pointed to cost or loss of coverage. Gastrointestinal side effects accounted for 28%, while adherence and clinical reassessment formed smaller shares.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">This matters because it\u00a0reframes\u00a0the real-world challenge. Side effects are important, but they are not the dominant continuation barrier in the\u00a0MDForLives\u00a0findings. Affordability is.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">In the USA, this pattern appears especially strong, with\u00a0nearly 70%\u00a0of clinicians citing financial disruption as the leading reason for discontinuation. In the UK, the picture is more distributed, with service pathways, review processes, and prescribing limitations playing a more visible role.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">For clinicians, stopping\u00a0a therapy\u00a0because it is not working is one thing. Stopping a therapy that may be working because access collapses\u00a0is\u00a0different. That experience can influence future prescribing conversations and make clinicians more guarded when starting treatment.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<h2 aria-level=\"2\"><span class=\"ez-toc-section\" id=\"Patient_Expectations_May_Be_the_Most_Underestimated_Risk\"><\/span><strong>Patient Expectations May Be the Most Underestimated Risk\u00a0<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span data-contrast=\"auto\">Only about one-quarter of clinicians believe patients\u00a0generally understand\u00a0the long-term nature of GLP-1 therapy.\u00a0More than half describe patient understanding as partial, and more than 20% say expectations are often misunderstood.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">This is not a small communication gap. It affects adherence, persistence, and trust.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Patients may approach GLP-1\u00a0therapy\u00a0expecting rapid weight loss or short-term treatment. Clinicians, however, are increasingly framing obesity as a chronic condition requiring sustained management. When those two expectations are misaligned, the treatment journey becomes vulnerable.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">If access barriers arise, if side effects appear, or if progress slows, patients who were not prepared for long-term care may be more likely to stop.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">This makes expectation-setting a clinical intervention in itself.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<h2 aria-level=\"2\"><span class=\"ez-toc-section\" id=\"The_Future_Impact_of_GLP-1_Therapy_Will_Be_Decided_Beyond_the_Prescription\"><\/span><strong>The Future Impact of GLP-1 Therapy Will Be Decided Beyond the Prescription\u00a0<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><img loading=\"lazy\" decoding=\"async\" data-attachment-id=\"15102\" data-permalink=\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/in-article-image-2-2\/\" data-orig-file=\"https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/In-Article-Image-2-1.png\" data-orig-size=\"800,400\" data-comments-opened=\"1\" data-image-meta=\"{&quot;aperture&quot;:&quot;0&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;0&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;0&quot;,&quot;iso&quot;:&quot;0&quot;,&quot;shutter_speed&quot;:&quot;0&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;0&quot;,&quot;alt&quot;:&quot;&quot;}\" data-image-title=\"In-Article Image 2\" data-image-description=\"\" data-image-caption=\"\" data-medium-file=\"https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/In-Article-Image-2-1-300x150.png\" data-large-file=\"https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/In-Article-Image-2-1.png\" class=\"aligncenter size-full wp-image-15102\" src=\"https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/In-Article-Image-2-1.png\" alt=\"GLP-1 obesity care depends on coverage affordability adherence and patient expectations\" width=\"800\" height=\"400\" srcset=\"https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/In-Article-Image-2-1.png 800w, https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/In-Article-Image-2-1-300x150.png 300w, https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/In-Article-Image-2-1-768x384.png 768w\" sizes=\"auto, (max-width: 800px) 100vw, 800px\" \/><\/p>\n<p><span data-contrast=\"auto\">When clinicians looked ahead,\u00a0nearly 65%\u00a0identified\u00a0expanded coverage and affordability as the most\u00a0important factor\u00a0shaping the future impact of GLP-1 therapy in obesity care. Another 18% pointed to better long-term adherence strategies.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Clearer guidance and stronger real-world evidence were less\u00a0frequently\u00a0selected.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">That finding is telling. For many clinicians, the scientific case is already strong enough. The unresolved question is whether healthcare systems can support sustained use fairly, predictably, and at scale.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">This is where GLP-1 therapy now sits: clinically effective, increasingly accepted, but operationally fragile.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<h2 aria-level=\"2\"><span class=\"ez-toc-section\" id=\"Closing_Perspective\"><\/span><strong>Closing Perspective\u00a0<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><span data-contrast=\"auto\">GLP-1 therapy\u00a0represents\u00a0one of the most important advances in obesity care in recent years. It has changed how clinicians think about pharmacologic weight management and strengthened the case for treating obesity as a chronic condition.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">But the\u00a0MDForLives\u00a0findings suggest that real-world impact will depend less on whether clinicians believe in GLP-1 therapy and more on whether patients can stay on it.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">The next phase of obesity care will not be defined by initiation alone. It will be defined by continuity.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Until access frameworks, affordability, patient expectations, and long-term care pathways catch up with clinical confidence, GLP-1 therapy will remain caught between strong therapeutic promise and uneven real-world delivery.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<h2 aria-level=\"2\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3 aria-level=\"2\"><span class=\"ez-toc-section\" id=\"Why_is_GLP-1_continuation_important_in_obesity_care\"><\/span><span style=\"color: #000000;\"><b style=\"font-size: 26px;\">Why is GLP-1 continuation important in obesity care?<\/b><\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span data-contrast=\"auto\">GLP-1 therapy is\u00a0generally used\u00a0as part of long-term obesity management. If treatment is interrupted early, patients may not achieve or\u00a0maintain\u00a0the expected clinical benefit.<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_barriers_to_GLP-1_continuation\"><\/span><span style=\"color: #000000;\"><b style=\"font-size: 26px;\">What are the main barriers to GLP-1 continuation?<\/b><\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span data-contrast=\"auto\">In the\u00a0MDForLives\u00a0clinician-reported research, cost or loss of coverage was the\u00a0most commonly cited\u00a0barrier to long-term continuation, followed by gastrointestinal side effects.<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"Are_GLP-1_therapies_considered_relevant_for_obesity_treatment_without_diabetes\"><\/span><span style=\"color: #000000;\"><b>Are GLP-1 therapies considered relevant for obesity treatment without diabetes?<\/b><\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span data-contrast=\"auto\">Yes. More than 90% of clinicians in the\u00a0MDForLives\u00a0research described GLP-1 or GLP-1\/GIP therapies as highly or moderately relevant to obesity management.<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_GLP-1_outcomes_differ_between_clinical_trials_and_real-world_care\"><\/span><span style=\"color: #000000;\"><b>Why do GLP-1 outcomes differ between clinical trials and real-world care?<\/b><\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span data-contrast=\"auto\">Real-world outcomes may be affected by delayed titration, access interruptions, cost barriers, side effects, adherence challenges, and differences in patient support.<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_will_shape_the_future_of_GLP-1_therapy_in_obesity_care\"><\/span><span style=\"color: #000000;\"><b>What will shape the future of GLP-1 therapy in obesity care?<\/b><\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span data-contrast=\"auto\">Clinicians in the\u00a0MDForLives\u00a0research most often\u00a0identified\u00a0expanded coverage and affordability as the key factor that will influence future real-world impact.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A GLP-1 prescription can begin with clinical confidence and still end in uncertainty.\u00a0 That is the tension now shaping obesity care. The question is no longer only whether GLP-1 and GLP-1\/GIP therapies can support meaningful weight loss. The more\u00a0difficult question\u00a0is whether patients can stay on them long enough for that benefit to translate into durable care.\u00a0 Globally, obesity is increasingly being treated as a chronic, relapsing condition rather than a short-term lifestyle problem. The World Health Organization\u2019s 2025 guidance on GLP-1 therapies for obesity reinforces this shift, positioning treatment within a broader model that includes long-term care, healthy diets, physical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":15100,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[2493],"tags":[],"class_list":["post-15094","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-obesity"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v23.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>GLP-1 Therapy in Obesity Care: Continuation &amp; Access Gaps<\/title>\n<meta name=\"description\" content=\"Discover how access, affordability, patient expectations, &amp; treatment continuation influence real-world impact GLP-1 therapy in obesity care.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GLP-1 Therapy in Obesity Care: Why Staying on Treatment Is the Real Test\" \/>\n<meta property=\"og:description\" content=\"Discover how access, affordability, patient expectations, &amp; treatment continuation influence real-world impact GLP-1 therapy in obesity care.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/\" \/>\n<meta property=\"og:site_name\" content=\"Medical Market Research Blog | A Blog about Healthcare Survey\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/MDforLives\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-23T13:40:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/Featured-Image-Banner-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"390\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"MDForLives\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@mdforlives\" \/>\n<meta name=\"twitter:site\" content=\"@mdforlives\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"MDForLives\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/\",\"url\":\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/\",\"name\":\"GLP-1 Therapy in Obesity Care: Continuation & Access Gaps\",\"isPartOf\":{\"@id\":\"https:\/\/mdforlives.com\/blog\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/Featured-Image-Banner-1.png\",\"datePublished\":\"2026-06-23T13:40:33+00:00\",\"dateModified\":\"2026-06-23T13:40:33+00:00\",\"author\":{\"@id\":\"https:\/\/mdforlives.com\/blog\/#\/schema\/person\/e01110c035039a159c4de9ed6c978482\"},\"description\":\"Discover how access, affordability, patient expectations, & treatment continuation influence real-world impact GLP-1 therapy in obesity care.\",\"breadcrumb\":{\"@id\":\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#primaryimage\",\"url\":\"https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/Featured-Image-Banner-1.png\",\"contentUrl\":\"https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/Featured-Image-Banner-1.png\",\"width\":1200,\"height\":390,\"caption\":\"clinician and patient reviewing a GLP-1 obesity care continuation pathway\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/mdforlives.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GLP-1 Therapy in Obesity Care: Why Staying on Treatment Is the Real Test\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mdforlives.com\/blog\/#website\",\"url\":\"https:\/\/mdforlives.com\/blog\/\",\"name\":\"Medical Market Research Blog | A Blog about Healthcare Survey\",\"description\":\"MDForLives\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mdforlives.com\/blog\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/mdforlives.com\/blog\/#\/schema\/person\/e01110c035039a159c4de9ed6c978482\",\"name\":\"MDForLives\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mdforlives.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/187b3a34b26b0c9220fd4f2de6744b5d4b17b2d8582eaf5d68e347b037648de4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/187b3a34b26b0c9220fd4f2de6744b5d4b17b2d8582eaf5d68e347b037648de4?s=96&d=mm&r=g\",\"caption\":\"MDForLives\"},\"description\":\"MDForLives is a global healthcare intelligence platform where real-world perspectives are transformed into validated insights. We bring together diverse healthcare experiences to discover, share, and shape the future of healthcare through data-backed understanding.\",\"sameAs\":[\"https:\/\/mdforlives.com\/blog\/\"],\"url\":\"https:\/\/mdforlives.com\/blog\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GLP-1 Therapy in Obesity Care: Continuation & Access Gaps","description":"Discover how access, affordability, patient expectations, & treatment continuation influence real-world impact GLP-1 therapy in obesity care.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/","og_locale":"en_US","og_type":"article","og_title":"GLP-1 Therapy in Obesity Care: Why Staying on Treatment Is the Real Test","og_description":"Discover how access, affordability, patient expectations, & treatment continuation influence real-world impact GLP-1 therapy in obesity care.","og_url":"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/","og_site_name":"Medical Market Research Blog | A Blog about Healthcare Survey","article_publisher":"https:\/\/www.facebook.com\/MDforLives","article_published_time":"2026-06-23T13:40:33+00:00","og_image":[{"width":1200,"height":390,"url":"https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/Featured-Image-Banner-1.png","type":"image\/png"}],"author":"MDForLives","twitter_card":"summary_large_image","twitter_creator":"@mdforlives","twitter_site":"@mdforlives","twitter_misc":{"Written by":"MDForLives","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/","url":"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/","name":"GLP-1 Therapy in Obesity Care: Continuation & Access Gaps","isPartOf":{"@id":"https:\/\/mdforlives.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#primaryimage"},"image":{"@id":"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#primaryimage"},"thumbnailUrl":"https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/Featured-Image-Banner-1.png","datePublished":"2026-06-23T13:40:33+00:00","dateModified":"2026-06-23T13:40:33+00:00","author":{"@id":"https:\/\/mdforlives.com\/blog\/#\/schema\/person\/e01110c035039a159c4de9ed6c978482"},"description":"Discover how access, affordability, patient expectations, & treatment continuation influence real-world impact GLP-1 therapy in obesity care.","breadcrumb":{"@id":"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#primaryimage","url":"https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/Featured-Image-Banner-1.png","contentUrl":"https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/Featured-Image-Banner-1.png","width":1200,"height":390,"caption":"clinician and patient reviewing a GLP-1 obesity care continuation pathway"},{"@type":"BreadcrumbList","@id":"https:\/\/mdforlives.com\/blog\/glp-1-therapy-in-obesity-care\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/mdforlives.com\/blog\/"},{"@type":"ListItem","position":2,"name":"GLP-1 Therapy in Obesity Care: Why Staying on Treatment Is the Real Test"}]},{"@type":"WebSite","@id":"https:\/\/mdforlives.com\/blog\/#website","url":"https:\/\/mdforlives.com\/blog\/","name":"Medical Market Research Blog | A Blog about Healthcare Survey","description":"MDForLives","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mdforlives.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/mdforlives.com\/blog\/#\/schema\/person\/e01110c035039a159c4de9ed6c978482","name":"MDForLives","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mdforlives.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/187b3a34b26b0c9220fd4f2de6744b5d4b17b2d8582eaf5d68e347b037648de4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/187b3a34b26b0c9220fd4f2de6744b5d4b17b2d8582eaf5d68e347b037648de4?s=96&d=mm&r=g","caption":"MDForLives"},"description":"MDForLives is a global healthcare intelligence platform where real-world perspectives are transformed into validated insights. We bring together diverse healthcare experiences to discover, share, and shape the future of healthcare through data-backed understanding.","sameAs":["https:\/\/mdforlives.com\/blog\/"],"url":"https:\/\/mdforlives.com\/blog\/author\/admin\/"}]}},"jetpack_featured_media_url":"https:\/\/mdforlives.com\/blog\/wp-content\/uploads\/2026\/06\/Featured-Image-Banner-1.png","jetpack_likes_enabled":true,"jetpack-related-posts":[],"jetpack_shortlink":"https:\/\/wp.me\/pfwvRY-3Vs","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/mdforlives.com\/blog\/wp-json\/wp\/v2\/posts\/15094","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mdforlives.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mdforlives.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mdforlives.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mdforlives.com\/blog\/wp-json\/wp\/v2\/comments?post=15094"}],"version-history":[{"count":3,"href":"https:\/\/mdforlives.com\/blog\/wp-json\/wp\/v2\/posts\/15094\/revisions"}],"predecessor-version":[{"id":15105,"href":"https:\/\/mdforlives.com\/blog\/wp-json\/wp\/v2\/posts\/15094\/revisions\/15105"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mdforlives.com\/blog\/wp-json\/wp\/v2\/media\/15100"}],"wp:attachment":[{"href":"https:\/\/mdforlives.com\/blog\/wp-json\/wp\/v2\/media?parent=15094"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mdforlives.com\/blog\/wp-json\/wp\/v2\/categories?post=15094"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mdforlives.com\/blog\/wp-json\/wp\/v2\/tags?post=15094"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}